1. Home
  2. Medical News
  3. Psychiatry and Mental Health
advertisement

Antiseizure Dispensing Rises Around Antidementia Treatment

Illustrated brain with subtle neural activity cues representing antiseizure medicine dispensing around antidementia
11/17/2026

Key Takeaways

  • Australian adults initiating antidementia medicines had more antiseizure dispensing than matched controls, with the gap widening after initiation.
  • Valproate accounted for most of the later excess.
  • Levetiracetam dispensing rose before initiation without statistically significant individual annual pre-initiation differences, and the excess became clearer afterward.
  • Rematching on treated comorbidity narrowed the earlier gap, but the later gap persisted.
Seizures and behavioral or psychiatric symptoms can each prompt antiseizure prescribing among people receiving dementia medicines. The timing of dispensing around a first antidementia supply may help characterize this uncertainty, but a prescription alone cannot establish its indication.

Investigators used the de-identified 10% random sample of the Australian Pharmaceutical Benefits Scheme (PBS) for a retrospective, population-based matched-cohort study of antiseizure dispensing. They identified 4,385 matched pairs; initiators first received an antidementia medicine during 2018–2021.

Initiators were aged 50 or older and had no earlier observed antidementia supply; controls had no such dispensing during 2013–2024. Pairs matched on single-year age, sex, index year, and diabetes and hypertension medicine use. First observed supply defined index year zero, not a confirmed diagnosis. Primary pairs survived through the third year after index.

Annual antiseizure medication (ASM) supply was observed from five years before through three years after index. The outcome was Anatomical Therapeutic Chemical (ATC) N03 dispensing, excluding gabapentin and pregabalin. Investigators used paired McNemar comparisons and interrupted time-series analysis. Sensitivity analyses rematched on medicine-based Rx-Risk comorbidity, removed the survival requirement, and stratified by age and sex.

At year −5, ASM dispensing was recorded for 2.7% of initiators versus 1.8% of controls. By year +3, the proportions were 9.1% versus 2.4%, a case-to-control ratio of 3.85 with a 95% confidence interval (CI) of 3.13–4.75. The gap widened around and after initiation, but dispensing records cannot establish a treatment effect.

Valproate accounted for most of the later excess: at year +3, dispensing was 4.9% versus 0.7%, with a ratio of 6.97 (95% CI 4.80–10.12). Levetiracetam dispensing was 1.6% versus 0.7% at year +3. Its use among initiators began rising around year −3; individual annual case–control differences before initiation were not statistically significant, although the pre-initiation trajectories differed. The relative excess was greater in younger than older initiators, principally for valproate. Rematching on treated comorbidity narrowed the earlier gap but not the later one; removing the survival requirement yielded broadly similar patterns.

The investigators considered behavioral or psychiatric prescribing a possible explanation for much of the valproate excess and seizures a possible smaller contributor to the levetiracetam pattern. Neither indication was established for individuals. Recipients of antidementia medicines are a treated subgroup, not everyone with dementia or necessarily people with confirmed Alzheimer disease. First supply does not date symptom onset, diagnosis, or stage. Dispensing establishes neither indication nor consumption, and clinical benefits and harms were not tested. Unmeasured epilepsy, stroke, psychiatric conditions, and differences in clinical contact may confound comparisons. Requiring survival may select survivors; similar patterns without that requirement do not eliminate residual confounding.

Antiseizure dispensing was elevated before antidementia treatment and more so afterward, predominantly involving valproate. The data cannot determine the prescribing indication or show that antidementia treatment caused the pattern.

Clinician Questions

Which antidementia medicines defined treatment initiation in the Australian antiseizure-dispensing cohort?

The index medicines were the cholinesterase inhibitors donepezil, rivastigmine, and galantamine, or memantine. First observed dispensing of one of these medicines among Australian adults aged 50 or older defined treatment initiation, not a confirmed dementia or Alzheimer diagnosis.

Why were gabapentin and pregabalin excluded from the Australian cohort's antiseizure-dispensing outcome?

Among Australian adults starting antidementia medicines, gabapentin and pregabalin were excluded from the ATC N03 comparison because they are used mainly for neuropathic pain in Australia and are poor markers of seizure treatment. Investigators examined them separately as secondary outcomes without verifying anyone's reason for use.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free